C
Concentric Analgesics
Private, biotechnology company
About Concentric Analgesics
Concentric Analgesics is a healthcare startup that specializes in the development of novel pain management solutions. Their primary product is a unique TRPV1 Agonist Prodrug, which is designed to target pain at its source with minimal systemic exposure. This approach aims to reduce the reliance on opioids, which are currently the mainstay of pain treatment but come with significant side effects and increased costs.
The company's business model revolves around the development and sale of these prodrugs to healthcare providers. They operate in the pain management market, which is a significant segment of the healthcare industry due to the high prevalence of chronic pain, particularly in patients with advanced diseases such as cancer.
Concentric Analgesics' prodrugs offer several advantages over existing pain management solutions. They provide continuous and durable relief without causing numbness or weakness, which are common side effects of regional blocks. The prodrugs are also administered via a single injection, simplifying ongoing care.
The company's revenue comes from the sale of these prodrugs to healthcare providers. By offering a more effective and safer alternative to opioids and other pain management solutions, Concentric Analgesics has the potential to capture a significant share of the pain management market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Francisco, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 59.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLEOther financing | Jan 2022 | $20M | — | Undisclosed | ↗ |
| SERIES BOther financing | May 2019 | $76M | $304M | Venrock · Cowen Group · Kern Whelan Capital · Oracle Investment Management | — |
Growth signals
Latest recorded traffic for Concentric Analgesics is 310 monthly website visits, down 77.9% over the last three months. Concentric Analgesics's team declined 60% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- OMOracle Investment Management
Venrock
Cowen Group- KCKern Whelan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Concentric Analgesics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Concentric Analgesics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.